Biomea Fusion, Inc.

Contributing Author

Recent Articles by Biomea Fusion, Inc.

Nov-10	Biomea Fusion to Participate at Jefferies London Healthcare Conference BMEA GlobeNewswire
Nov-05	Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek 2025 BMEA GlobeNewswire
Nov-04	Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights BMEA GlobeNewswire
Oct-30	Biomea Fusion to Present Poster Presentations at ObesityWeek2025 BMEA GlobeNewswire
Oct-27	Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist BMEA GlobeNewswire
Oct-21	Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series BMEA GlobeNewswire
Oct-07	Biomea Fusion Announces Pricing of Public Offering of Securities BMEA GlobeNewswire
Oct-06	Biomea Fusion Announces Proposed Public Offering of Securities BMEA GlobeNewswire
Oct-06	Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations BMEA GlobeNewswire
Oct-01	Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) BMEA GlobeNewswire
Sep-16	Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update BMEA GlobeNewswire
Aug-05	Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights BMEA GlobeNewswire
Jul-24	Biomea Fusion Appoints Julianne Averill to its Board of Directors BMEA GlobeNewswire
Jun-23	Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA) BMEA GlobeNewswire
Jun-18	Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates BMEA GlobeNewswire
Jun-17	Biomea Fusion Announces Pricing of Public Offering of Securities BMEA GlobeNewswire
Jun-17	Biomea Fusion Announces Proposed Public Offering of Securities BMEA GlobeNewswire
Jun-13	Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025 BMEA GlobeNewswire
May-14	Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia BMEA GlobeNewswire
May-05	Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights BMEA GlobeNewswire

Biomea Fusion, Inc.

Recent Articles by Biomea Fusion, Inc.

Upgrade your FINVIZ experience